Effective delivery of drugs

Background

There are a number of impediments to effective drug delivery. These can include erroneous absorption which reduces the concentration of the drug at the critical target site. In order to overcome this, researchers at the University of Strathclyde have pioneered a technique which delivers drugs through the use of a proprietary delivery system.

Technology

Our proprietary delivery systems are microscopic shipping vessels which act as transporters of the entrapped drug and preferentially target it to phagocytic cells within a tissue. Administration of these drug loaded particles by inhalation allows non-invasive drug delivery to be realised, minimising repeat administrations due to increased efficacy. This platform technology can be used for a number of applications in treatment of lung conditions such as infectious diseases, cancer, asthma, or emerging diseases such as SARS.

Key benefits

  • reductions in drug doses given and concentrations can be achieved due to the increased efficiency of the system
  • toxic drugs can be given in lower quantities
  • different types of formulations can be produced

Markets & applications

The market potential of this delivery system is broad as it is a platform technology. Previous studies have already demonstrated that the delivery system can deliver drugs after intravenous injection and new studies focus on the use of this technology for lung delivery.

Licensing & development

Our proprietary delivery system has been patented and is owned by the University of Strathclyde. Contact is welcomed from organisations interested in developing, licensing or exploiting this technology. For further information, please contact the RKES team quoting reference number 1720.

This project has received assistance from the Proof of Concept Programme managed by Scottish Enterprise.  The Proof of Concept Programme supports the pre-commercialisation of leading-edge technologies emerging from Scotland's universities, research institutes and NHS Trusts.